Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative activity against nine cancer cell lines in vitro. Flow cytometric analyses showed that the compound caused G2-M arrest, which occurred mainly at the mitotic phase. In addition, immunofluorescence microscopy and in vitro tubulin polymerization studies showed that 5HPP-33 has antimicrotubule activity with a paclitaxel-like mode of action. It is effective against four different paclitaxel-resistant cell lines. Thus, 5HPP-33 represents a potential antitumor agent.

Original publication

DOI

10.1158/1535-7163.MCT-05-0254

Type

Journal article

Journal

Mol Cancer Ther

Publication Date

02/2006

Volume

5

Pages

450 - 456

Keywords

Animals, Antimitotic Agents, Antineoplastic Agents, Cell Cycle, Cell Line, Tumor, Drug Resistance, Neoplasm, Humans, Indoles, Isoindoles, Mice, Paclitaxel, Tubulin, Tubulin Modulators